Sidley represented Cellomics, a leading Hong Kong-based biotech company focusing on development and commercialization of liquid biopsy products for cancer screening and early detection, in its Series B+ financing. The lead investor is an equity fund of a Hong Kong-listed insurance company.
We previously advised Cellomics’ Series B financing led by Raffles Family Office with the participation of existing shareholders, including Jacobson Pharma and Sinocare.
The Sidley team was led by partners Raymond Oh and Meng Ding with support from senior associate Selina Wong and managing associate Eldon Chan.
Sidley provides multidisciplinary services for life sciences clients. We advise clients across the full spectrum of their business life cycles, ranging from formation, corporate governance, and compliance operations for startups to collaboration, licensing, commercialization, and filing in the business development phase, including initial public offerings, equity financings, and bond/note issuances as well as domestic and cross-border mergers and acquisitions, asset restructuring, equity incentive plans, and privatizations.